This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus Weight-Loss Pill Works - FDA

MOUNTAIN VIEW, Calif. ( TheStreet) -- In a review posted to its Web site Tuesday, U.S. drug regulators said Vivus' (VVUS - Get Report) weight-loss drug Qnexa was effective in helping obese patients shed pounds, but the agency raised questions -- most of them expected -- about the drug's safety.

Vivus shares were up about 34% to $14.25 in Tuesday's pre-market trading session as anxious investors breathed a sigh of relief over the U.S. Food and Drug Administration's relatively benign review of Qnexa, which didn't yield any "Uh Oh!" revelations about the drug's safety.

The FDA will convene an outside panel of experts Thursday -- which TheStreet will be covering via live blog -- to review Vivus' approval application for the weight-loss drug Qnexa. Vivus is trying to become the first company in more than a decade to gain U.S. approval for a new weight-loss drug. Two other companies -- Arena Pharmaceuticals (ARNA - Get Report) and Orexigen Therapeutics (OREX - Get Report) -- are fast on its heels.

In the FDA's review of Qnexa, posted online Tuesday as part of the briefing documents for Thursday's advisory panel, pooled data from two large phase III studies demonstrated that patients treated with low, medium and high doses Qnexa lost between 3 percent, 7 percent and 9 percent of their body weight, respectively, adjusted for the weight-loss reported for patients treated with a placebo.

Twenty percent of placebo-treated patients lost more than 5% of their body weight, compared to 45 percent, 62 percent and 69 percent of Qnexa patients.

According to the efficacy criteria laid out by FDA for weight-loss drugs in 2007, the FDA concluded that, "all three doses of PHEN/TPM [Qnexa] were efficacious for weight loss."

Qnexa's safety and not the drug's ability to help patients lose weight, was the major concern entering Thursday's meeting. In its briefing document Tuesday, FDA's safety review highlights five areas of "particular interest" related to Qnexa -- pregnancy risk, psychiatric-related adverse events, cognitive-related adverse events, metabolic acidosis and cardiovascular events.

All of these safety issues had been anticipated by investors as major areas of discussion at Thursday's panel. The FDA chose not to state its own opinion of Qnexa's overall safety in Tuesday's review documents.

"The FDA's briefing documents contained no smoking guns," related to Qnexa's safety, said JMP Securities analyst Jason Butler. He has an outperform rating on Vivus with an $18 price target.

Vivus' Qnexa consists of two currently approved drug: The generic weight-loss drug phentermine and topirimate, a drug used to treat epilepsy and migraine, marketed as Topomax by Johnson & Johnson (JNJ).

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.58 -0.32%
OREX $0.41 -5.70%
VVUS $1.37 0.00%
AAPL $93.24 -0.41%
FB $117.81 -0.21%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs